FindTrial
Sign In

The optimal dose of nalbuphine in painless artificial abortion and its clinical effects compare with equivalent sufentanil

The optimal dose of nalbuphine in painless artificial abortion and its clinical effects compare with equivalent sufentanil

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17011263
Enrollment
Unknown
Registered
2017-04-29
Start date
2017-05-02
Completion date
Unknown
Last updated
2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless artificial abortion

Interventions

Group of nalbuphine:Nalbuphine as the analgesic
Group of sufentanil:Sufentanil as the analgesic

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: women who were voluntary to accept painless artificial abortion with early pregnancy, less than 10 weeks gestation, aged 18 years or older, ASA I to III.

Exclusion criteria

Exclusion criteria: Exclusion of allergy to related drug, coagulopathy, severe liver and renal diseases,inability to comprehend study-related procedures.

Design outcomes

Primary

MeasureTime frame
Pain score after operation;the time to resuscitation;hospitalized duration;—

Secondary

MeasureTime frame
Duration of surgery;the dose of propofol;intraoperative respiratory depression;nausea / vomiting;body movement;—

Countries

China

Contacts

Public ContactXuzhong Xu

The First Affiliated Hospital of Wenzhou Medical University

xuzhong@263.net+86 13706657799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026